Crossmark

Selecting Core Outcomes for Randomised Effectiveness trials In Type 2 Diabetes (SCORE-IT): study protocol for the development of a core outcome set

Crossref DOI link: https://doi.org/10.1186/s13063-018-2805-2

Published Online: 2018-08-07

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

,

Harman, Nicola L. https://orcid.org/0000-0001-6958-6466
Wilding, John

Curry, Dave

Harris, James

Logue, Jennifer

Pemberton, R. John

Perreault, Leigh

Thompson, Gareth

Tunis, Sean

Williamson, Paula R.
Funding

Funding for this research was provided by:

Horizon 2020 (654248)
License Information

Text and Data Mining valid from 2018-08-07
More Information

Article History

Received: 11 April 2018

Accepted: 10 July 2018

First Online: 7 August 2018

Ethics approval and consent to participate

: Ethical approval for consensus methods has been obtained from the University of Liverpool Health and Life Sciences Research Ethics Committee (Human participants, tissues and databases) (ref: 3306). All participants of the consensus process provide online proportional consent prior to undertaking the online survey.

: Not applicable.

: PRW is member of the COMET Management Group and co-applicant on grants to support COMET and related work.JW has received lecture fees from AstraZeneca, Boehringer Ingelheim, Janssen, Lilly, Novo Nordisk and Orexigen & Sanofi; consultancy (institutional) from AstraZeneca, Boehringer Ingelheim, Janssen, Lilly, Napp, Novo Nordisk and Orexigen; and grants to institution from Takeda, Novo Nordisk and AstraZeneca.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.